Welcome to our dedicated page for Vaccinex news (Ticker: VCNX), a resource for investors and traders seeking the latest updates and insights on Vaccinex stock.
Vaccinex, Inc. (VCNX) generates frequent news as a clinical-stage biotechnology company advancing pepinemab, a monoclonal antibody targeting semaphorin 4D (SEMA4D), in neurodegenerative disease and oncology. News coverage for VCNX often centers on clinical trial updates, scientific presentations, and partnering activity related to its lead programs.
Investors and researchers following VCNX news can expect detailed reports on the Phase 1b/2 SIGNAL-AD trial in Alzheimer’s disease, including biomarker and cognitive data in Mild Cognitive Impairment and mild dementia. Releases also describe findings from a prior randomized Phase 2 study in Huntington’s disease and how these results inform the company’s broader neurodegenerative strategy.
On the oncology side, Vaccinex news frequently highlights data from the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer and a Phase 1b/2 trial in metastatic pancreatic adenocarcinoma, where pepinemab is combined with immune checkpoint inhibitors such as KEYTRUDA and BAVENCIO. Company updates discuss how pepinemab appears to promote mature tertiary lymphoid structures in tumors and may enhance the clinical activity of checkpoint therapies, particularly in HPV-negative and PD-L1-low head and neck cancer and metastatic melanoma.
Additional VCNX news items cover collaborations and project agreements using the ActivMAb antibody discovery platform with multiple biopharmaceutical partners, as well as corporate developments such as financing transactions and changes in stock listing status, including the transition from Nasdaq to OTC quotation. For users tracking Vaccinex, this news stream offers ongoing insight into trial progress, scientific rationale, partnerships and regulatory or listing milestones related to the VCNX symbol.
Vaccinex (Nasdaq: VCNX), a clinical-stage biotech company focusing on neurodegenerative disease treatment, has announced the exercise of outstanding warrants resulting in $6.2 million in gross proceeds. The transaction involves:
1. Immediate exercise of warrants to purchase 1,067,492 shares at $5.636 per share
2. Issuance of 827,483 shares and pre-funding of 240,009 shares
3. New warrants issued for up to 1,601,238 additional shares at $5.636 per share, expiring in 5 years
Notably, entities affiliated with the CEO and Board Chairman accounted for 51% of the securities in the transaction. The closing is expected on September 18, 2024, subject to customary conditions.
Vaccinex (VCNX) has reported positive results from its SIGNAL-AD Phase 1b/2 trial of pepinemab in early-stage Alzheimer's disease (AD). The study showed a statistically significant difference (p=0.0297) in FDG-PET signal in the medial temporal cortex after 12 months of treatment compared to placebo. Pepinemab was well-tolerated in AD patients.
Key findings include:
- Reduction in blood levels of GFAP (astrocyte reactivity marker) and p-tau 217 (neuronal damage marker) in patients with Mild Cognitive Impairment (MCI) due to AD
- Apparent slowing of cognitive decline in MCI patients, as measured by iADRS and ADAS-Cog 13 assessments
- No discernible effect on biomarkers or cognitive decline in patients with early dementia
Vaccinex aims to pursue a development partnership for continued research in AD and other neurodegenerative diseases, including Huntington's Disease.
Vaccinex (VCNX) reported positive results from its SIGNAL-AD Phase 1b/2 trial of pepinemab in Alzheimer's Disease (AD). The trial met its primary safety endpoint, with no serious treatment-related adverse events. A key secondary endpoint showed statistically significant improvement in brain metabolic activity in patients with Mild Cognitive Impairment (MCI) due to AD.
The results mirror previous findings in Huntington's disease, suggesting pepinemab's potential efficacy in early-stage neurodegenerative diseases. While not powered for cognitive effects, the study indicates pepinemab may be most effective in early MCI stages. Vaccinex is exploring late-stage development partnerships for AD treatment.
Vaccinex (Nasdaq: VCNX) will present topline data for its phase 1b/2 SIGNAL-AD study of pepinemab in Alzheimer's disease at the Alzheimer's Association International Conference on July 31, 2024. The study aims to evaluate the safety and efficacy of targeting reactive astrocytes with pepinemab, a SEMA4D blocking antibody.
Key outcomes will include safety, tolerability, and the impact on brain metabolic activity and astrocyte reactivity. The company hypothesizes that pepinemab can slow disease progression by blocking SEMA4D signaling in astrocytes. Vaccinex believes pepinemab could be an attractive alternative or complementary treatment to anti-Aβ antibodies like Leqembi™ or Kisunla™, given its different mechanism of action and good tolerability in previous trials.
Vaccinex announced the completion of the last patient visit in its Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's Disease (AD). The database lock is expected in June, with key outcomes to be reported in July.
Pepinemab targets astrocyte reactivity and neuroinflammation, believed to accelerate AD progression. Key endpoints include safety, tolerability, brain metabolic activity, and biomarkers like GFAP and p-tau 217. The study also uses cognitive scales to assess treatment effects on cognitive decline.
Funded partly by $4.75 million from the Alzheimer’s Drug Discovery Foundation and a $0.75 million grant from the Alzheimer’s Association, pepinemab has shown potential to offer alternative or complementary treatment to existing anti-Aβ therapies.
Vaccinex has announced its first quarter 2024 financial results and updates on the SIGNAL-AD Phase 2a study for Alzheimer’s disease treatment using pepinemab. The last patient visit is scheduled for early June 2024, with data analysis by early July. Key highlights include the study's potential to slow neurodegenerative disease progression, funded partly by $4.75 million from the Alzheimer's Drug Discovery Foundation, and $0.75 million from the Alzheimer's Association. Financial highlights feature cash equivalents of $3.0 million, reductions in R&D expenses to $3.4 million, and a net loss decrease to $3.9 million. However, Nasdaq has flagged the company for non-compliance with equity standards. In response, Vaccinex has submitted a compliance plan.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Vaccinex (VCNX)?
What is the market cap of Vaccinex (VCNX)?
